Li Qiang, Wang Juntian, Zhang Guodong, Wang Jian, Yang Bin, Zhang Zhongtao
Department of General Surgery, Beijing Friendship Hospital, Capital Medical University; Beijing Key Laboratory of Cancer Invasion and Metastasis Research & National Clinical Research Center for Digestive Diseases, Beijing, China Department of General Surgery, Shanxi Province Cancer Hospital, Shanxi Medical University, Taiyuan, Shanxi, China.
Department of General Surgery, Shanxi Province Cancer Hospital, Shanxi Medical University, Taiyuan, Shanxi, China.
Jpn J Clin Oncol. 2016 Apr;46(4):323-8. doi: 10.1093/jjco/hyw001. Epub 2016 Feb 4.
Laparoscopy-assisted gastrectomy for advanced gastric cancer still remains controversial. The aim of this study is to compare oncologic feasibility and technical safety of laparoscopic versus open gastrectomy for advanced gastric cancer with D2 lymphadenectomy by comparing patients' short-term postoperative outcomes.
One hundred and one patients with laparoscopy-assisted gastrectomy and 101 patients with open gastrectomy were one-to-one matched and then compared in terms of operative outcomes and hospital courses.
The laparoscopic group showed significantly longer operating time (297.4 vs. 198.1 min, P < 0.001), earlier first flatus time (2.8 vs. 3.6 days, P < 0.001), earlier diet start time (3.8 vs. 4.6 days, P < 0.001), shorter hospital stay (10.5 vs. 11.9 days, P < 0.001) and less morbidity (21.8 vs. 37.6%, P = 0.019). However, retrieval lymph nodes, intraoperative blood loss, transfused patients, postoperative fever and mortality were similar in the two groups. As for complications, incision infection (1.0 vs. 8.9%, P = 0.021) was significantly more common in the open group than in the laparoscopic group. In the subgroup comparisons of outcomes of laparoscopy-assisted gastrectomy, the tumor, node, metastasis III group showed significantly increased retrieval lymph nodes (37.2 vs. 31.0, P < 0.001), increased intraoperative blood loss (147.2 vs. 120.5 ml, P = 0.010), increased length of hospital stay (11.1 vs. 9.9 days, P < 0.001) and increased morbidity (32.6 vs. 13.8%, P = 0.024) when compared with the tumor, node, metastasis II group.
Laparoscopy-assisted gastrectomy is feasible and safe for the treatment of advanced gastric cancer with D2 lymphadenectomy compared with open gastrectomy. Higher-level tumor stage (tumor, node, metastasis III) may increase the operative risk and should be performed with caution by surgeons with considerable experience of laparoscopic gastrectomy.
腹腔镜辅助胃癌根治术治疗进展期胃癌仍存在争议。本研究旨在通过比较患者术后短期结局,比较腹腔镜与开腹胃癌根治术加D2淋巴结清扫治疗进展期胃癌的肿瘤学可行性和技术安全性。
101例行腹腔镜辅助胃癌根治术的患者与101例行开腹胃癌根治术的患者进行一对一匹配,然后比较手术结局和住院过程。
腹腔镜组手术时间明显更长(297.4对198.1分钟,P<0.001),首次排气时间更早(2.8对3.6天,P<0.001),开始进食时间更早(3.8对4.6天,P<0.001),住院时间更短(10.5对11.9天,P<0.001),并发症发生率更低(21.8%对37.6%,P=0.019)。然而,两组的清扫淋巴结数、术中出血量、输血患者数、术后发热及死亡率相似。至于并发症,切口感染(1.0%对8.9%,P=0.021)在开腹组明显比腹腔镜组更常见。在腹腔镜辅助胃癌根治术结局的亚组比较中,肿瘤、淋巴结、转移III组与肿瘤、淋巴结、转移II组相比,清扫淋巴结数明显增加(37.2对31.0,P<0.001),术中出血量增加(147.2对120.5毫升,P=0.010),住院时间延长(11.1对9.9天,P<0.001),并发症发生率增加(32.6%对13.8%,P=0.024)。
与开腹胃癌根治术相比,腹腔镜辅助胃癌根治术加D2淋巴结清扫治疗进展期胃癌是可行且安全的。较高的肿瘤分期(肿瘤、淋巴结、转移III期)可能增加手术风险,应由有丰富腹腔镜胃癌根治术经验的外科医生谨慎实施。